Protagonist Therapeutics, Inc. (PTGX)

Market Cap	3.43B
Revenue (ttm)	207.80M
Net Income (ttm)	56.19M
Shares Out	61.98M
EPS (ttm)	0.86
PE Ratio	64.15
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	470,592
Open	56.02
Previous Close	56.44
Day's Range	55.17 - 56.71
52-Week Range	32.50 - 60.60
Beta	2.26
Analysts	Strong Buy
Price Target	67.11 (+21.29%)
Earnings Date	Aug 5, 2025

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 126
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX
• Website: https://www.protagonist-inc.com

Analyst Summary

According to 9 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price target is $67.11, which is an increase of 21.29% from the latest price.

Price Target

$67.11

(21.29% upside)

Analyst Consensus: Strong Buy